Christmas is coming early at Robbins Geller Rudman & Dowd after firm litigators struck a $1.21 billion deal to settle a securities fraud class action against Valeant Pharmaceuticals, which was represented by a team featuring Simpson Thacher & Bartlett partners Paul Curnin and Craig Waldman.

The company, now known as Bausch Health, announced the settlement in a press release on Monday.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]